Chardan Capital Reiterates Buy on Intellia Therapeutics, Maintains $107 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Intellia Therapeutics (NASDAQ:NTLA) and maintained a price target of $107.
August 07, 2023 | 8:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics' stock rating has been reiterated as 'Buy' by Chardan Capital, with a maintained price target of $107.
The reiteration of a 'Buy' rating by a reputable analyst like Geulah Livshits from Chardan Capital is a positive signal for investors. The maintained price target of $107 also indicates confidence in the company's future performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100